A citation-based method for searching scientific literature


List of co-cited articles
394 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
16

Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer.
Claudia Fumarola, Mara A Bonelli, Pier Giorgio Petronini, Roberta R Alfieri. Biochem Pharmacol 2014
299
14

Cancer Statistics, 2021.
Rebecca L Siegel, Kimberly D Miller, Hannah E Fuchs, Ahmedin Jemal. CA Cancer J Clin 2021
14


Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
9

PTEN and PI3K/AKT in non-small-cell lung cancer.
Cristina Pérez-Ramírez, Marisa Cañadas-Garre, Miguel Ángel Molina, María José Faus-Dáder, Miguel Ángel Calleja-Hernández. Pharmacogenomics 2015
145
7

PI3K/AKT/mTOR signaling as a molecular target in head and neck cancer.
Franziska E Marquard, Manfred Jücker. Biochem Pharmacol 2020
101
7

PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies.
Matthias Scheffler, Marc Bos, Masyar Gardizi, Katharina König, Sebastian Michels, Jana Fassunke, Carina Heydt, Helen Künstlinger, Michaela Ihle, Frank Ueckeroth,[...]. Oncotarget 2015
72
9

Cancer statistics, 2020.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2020
7

The biology and management of non-small cell lung cancer.
Roy S Herbst, Daniel Morgensztern, Chris Boshoff. Nature 2018
7

mTOR Signaling in Growth, Metabolism, and Disease.
Robert A Saxton, David M Sabatini. Cell 2017
6

Non-small cell lung cancer: current treatment and future advances.
Cecilia Zappa, Shaker A Mousa. Transl Lung Cancer Res 2016
795
6

Wnt signaling pathway in non-small cell lung cancer.
David J Stewart. J Natl Cancer Inst 2014
426
6

AKT as a Therapeutic Target for Cancer.
Mengqiu Song, Ann M Bode, Zigang Dong, Mee-Hyun Lee. Cancer Res 2019
300
6

Cancer statistics, 2019.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2019
6

Cancer statistics in China, 2015.
Wanqing Chen, Rongshou Zheng, Peter D Baade, Siwei Zhang, Hongmei Zeng, Freddie Bray, Ahmedin Jemal, Xue Qin Yu, Jie He. CA Cancer J Clin 2016
6

Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC.
Susan Heavey, Kenneth J O'Byrne, Kathy Gately. Cancer Treat Rev 2014
110
6

Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment.
Narjust Duma, Rafael Santana-Davila, Julian R Molina. Mayo Clin Proc 2019
626
6

clusterProfiler: an R package for comparing biological themes among gene clusters.
Guangchuang Yu, Li-Gen Wang, Yanyan Han, Qing-Yu He. OMICS 2012
5


Targeting PI3K/Akt/mTOR Signaling in Cancer.
Camillo Porta, Chiara Paglino, Alessandra Mosca. Front Oncol 2014
847
5

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
Suresh S Ramalingam, Johan Vansteenkiste, David Planchard, Byoung Chul Cho, Jhanelle E Gray, Yuichiro Ohe, Caicun Zhou, Thanyanan Reungwetwattana, Ying Cheng, Busyamas Chewaskulyong,[...]. N Engl J Med 2020
962
5


Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy.
Ferdinandos Skoulidis, John V Heymach. Nat Rev Cancer 2019
317
5

PIK3CA mutations and copy number gains in human lung cancers.
Hiromasa Yamamoto, Hisayuki Shigematsu, Masaharu Nomura, William W Lockwood, Mitsuo Sato, Naoki Okumura, Junichi Soh, Makoto Suzuki, Ignacio I Wistuba, Kwun M Fong,[...]. Cancer Res 2008
325
5

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.
Aravind Subramanian, Pablo Tamayo, Vamsi K Mootha, Sayan Mukherjee, Benjamin L Ebert, Michael A Gillette, Amanda Paulovich, Scott L Pomeroy, Todd R Golub, Eric S Lander,[...]. Proc Natl Acad Sci U S A 2005
5

Lung cancer: current therapies and new targeted treatments.
Fred R Hirsch, Giorgio V Scagliotti, James L Mulshine, Regina Kwon, Walter J Curran, Yi-Long Wu, Luis Paz-Ares. Lancet 2017
5

Lung Cancer 2020: Epidemiology, Etiology, and Prevention.
Brett C Bade, Charles S Dela Cruz. Clin Chest Med 2020
487
4


limma powers differential expression analyses for RNA-sequencing and microarray studies.
Matthew E Ritchie, Belinda Phipson, Di Wu, Yifang Hu, Charity W Law, Wei Shi, Gordon K Smyth. Nucleic Acids Res 2015
4

Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Jiri Polivka, Filip Janku. Pharmacol Ther 2014
534
4

The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling.
Boris Y Shorning, Manisha S Dass, Matthew J Smalley, Helen B Pearson. Int J Mol Sci 2020
143
4

Defining the role of mTOR in cancer.
David A Guertin, David M Sabatini. Cancer Cell 2007
4

Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.
Meran Keshawa Ediriweera, Kamani Hemamala Tennekoon, Sameera Ranganath Samarakoon. Semin Cancer Biol 2019
195
4

Targeting PI3K in cancer: mechanisms and advances in clinical trials.
Jing Yang, Ji Nie, Xuelei Ma, Yuquan Wei, Yong Peng, Xiawei Wei. Mol Cancer 2019
536
4


Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatment.
Haiying Cheng, Marina Shcherba, Gopichand Pendurti, Yuanxin Liang, Bilal Piperdi, Roman Perez-Soler. Lung Cancer Manag 2014
73
5

Role of Autophagy and Apoptosis in Non-Small-Cell Lung Cancer.
Guangbo Liu, Fen Pei, Fengqing Yang, Lingxiao Li, Amit Dipak Amin, Songnian Liu, J Ross Buchan, William C Cho. Int J Mol Sci 2017
216
4

PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around.
Anastasios Gkountakos, Giulia Sartori, Italia Falcone, Geny Piro, Ludovica Ciuffreda, Carmine Carbone, Giampaolo Tortora, Aldo Scarpa, Emilio Bria, Michele Milella,[...]. Cancers (Basel) 2019
46
8

Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas.
Yoh Dobashi, Shioto Suzuki, Hirochika Matsubara, Maiko Kimura, Shunsuke Endo, Akishi Ooi. Cancer 2009
40
10

Cancer statistics for the year 2020: An overview.
Jacques Ferlay, Murielle Colombet, Isabelle Soerjomataram, Donald M Parkin, Marion Piñeros, Ariana Znaor, Freddie Bray. Int J Cancer 2021
729
4

Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions.
Binaifer R Balsara, Jianming Pei, Yasuhiro Mitsuuchi, Robert Page, Andres Klein-Szanto, Hao Wang, Michael Unger, Joseph R Testa. Carcinogenesis 2004
236
4


The relation between PI3K/AKT signalling pathway and cancer.
Saeed Noorolyai, Neda Shajari, Elham Baghbani, Sanam Sadreddini, Behzad Baradaran. Gene 2019
164
4

Lung cancer.
Alesha A Thai, Benjamin J Solomon, Lecia V Sequist, Justin F Gainor, Rebecca S Heist. Lancet 2021
243
4

KEGG: kyoto encyclopedia of genes and genomes.
M Kanehisa, S Goto. Nucleic Acids Res 2000
4

Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas.
June-Koo Lee, Junehawk Lee, Sehui Kim, Soyeon Kim, Jeonghwan Youk, Seongyeol Park, Yohan An, Bhumsuk Keam, Dong-Wan Kim, Dae Seog Heo,[...]. J Clin Oncol 2017
243
3

EMT: 2016.
M Angela Nieto, Ruby Yun-Ju Huang, Rebecca A Jackson, Jean Paul Thiery. Cell 2016
3

Role of AKT and mTOR signaling pathways in the induction of epithelial-mesenchymal transition (EMT) process.
Mostafa Karimi Roshan, Arash Soltani, Anvar Soleimani, Kolsoum Rezaie Kahkhaie, Amir R Afshari, Mohammad Soukhtanloo. Biochimie 2019
103
3



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.